Skip to main content
IXHL logo

Incannex Healthcare Inc. (IXHL) Stock Price & Analysis

Incannex Healthcare Inc. (IXHL) — MoonshotScore 48/100 (Fair band), calculated Nov 18, 2026. Price $1.74 (-0.57%), as of the Nov 19, 2026 trading session; market cap $21.8M.

Educational signal · not a buy or sell recommendation · How to read this

$1.74 −$0.01 (-0.57%) Market Cap $21.8M

Incannex Healthcare Inc. · IXHL · NASDAQ

Incannex Healthcare Limited is an Australian pharmaceutical company focused on developing medicinal cannabinoid products. Their pipeline includes treatments for sleep apnea, traumatic brain injury, and inflammatory lung conditions.

Price as of Nov 19, 2026

Key Statistics

48 of 100

MoonshotScore v2 · Incannex Healthcare (IXHL)

Fair
Business Quality Average (51)
Financial Safety Okay (43)
Valuation Cheap (84)
Growth Durability Shrinking (8)
Momentum Slipping (22)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Cheap, but stalling growth, average quality and a middling balance sheet, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Average; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Shrinking; Momentum: Slipping.

  • quarterly revenue $66,616 (Q4 FY2025, quarter ended Jun 30, 2025)
  • EPS beat 4 of the last 8 reports
  • Altman Z 1.34 · Piotroski F 3

Holding back: soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IXHL (52 recorded, newest six shown)
RecordedScoreBand
41Weak
50Fair
50Fair
50Fair
48Fair
48Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.74
Change on the day-0.57%
Market capitalisation$21.8M—
Price / earnings (trailing)-0.22
Shares traded on the day194.3K

Price & events

Other perspectives

Council score for Incannex Healthcare (IXHL): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Neutral
Valuation Strong
Growth Durability Negative
Momentum Weak

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 12, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Oct 8, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Incannex Healthcare (IXHL), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Incannex Healthcare Inc. (IXHL) is listed on NASDAQ. It employs 12 people. In Q4 FY2025 it reported revenue of $66,616 and net income of -$36M. The market values it at $21.8M.

2 · Latest results

What do the latest results show for Incannex Healthcare (IXHL)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of $66,616. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025$66,616-$36M-$0.69 (diluted)
Q2 FY2025$108,987.2-$8M-$0.87 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Incannex Healthcare (IXHL)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is soft growth, weak price trend. The distress and quality screens read Altman Z 1.34 · Piotroski F 3. Trailing ratios: ROE -12.4% · ROA -11.8% · current ratio 67.79 · earnings yield -33.5% · free-cash-flow yield 6.1%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.34 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-12.4%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Incannex Healthcare (IXHL)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $700,000 · EPS -1.56 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q4 FY2025) was filed Sep 29, 2025 — 13 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Incannex Healthcare compare with its peers?

Short answer

Incannex Healthcare's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Cumberland Pharmaceuticals Inc. (CPIX) Same industry, near in market value$6.57 Nov 18, 2026$98.5M51 5-pillar Nov 18, 2026
Incannex Healthcare (IXHL) — this page$1.74$21.8M48
Organigram Global Inc. (OGI) Same industry, near in market value$0.63 Nov 19, 2026$88.9M35 5-pillar Nov 18, 2026
TherapeuticsMD, Inc. (TXMD) Same industry, near in market value$1.81 Nov 18, 2026$21.0M34 5-pillar Nov 18, 2026
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Same industry, near in market value$3.90 Nov 19, 2026$18.6M32 5-pillar Nov 18, 2026
Zhengye Biotechnology Holding Limited (ZYBT) Same industry, near in market value$1.50 Nov 18, 2026$71.1M32 5-pillar Nov 18, 2026
Talphera, Inc. (TLPH) Same industry, near in market value$0.74 Nov 19, 2026$38.4M31 5-pillar Nov 18, 2026
Quantum BioPharma Ltd. (QNTM) Same industry, near in market value$1.42 Nov 19, 2026$9.13M30 5-pillar Nov 18, 2026
Rockwell Medical, Inc. (RMTI) Same industry, near in market value$6.10 Nov 18, 2026$24.2M25 5-pillar Nov 18, 2026
Aytu BioPharma, Inc. (AYTU) Same industry, near in market value$2.66 Nov 18, 2026$28.9M25 5-pillar Nov 18, 2026
Biofrontera Inc. (BFRI) Same industry, near in market value$0.60 Nov 18, 2026$10.8M25 5-pillar Nov 18, 2026
CPHI (CPHI) Same industry, near in market value$0.50 Nov 19, 2026$21.7M23 5-pillar Nov 18, 2026
SCYNEXIS, Inc. (SCYX) Same industry, near in market value$2.60 Nov 19, 2026$25.9M23 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$700,000
EPS estimate
$-1.56

Measured against a quoted price of $1.74 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
7
Purchases
0
Sales
0
Other transactions
12

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IXHL in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IXHL in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Incannex Healthcare (IXHL)?

Read these with our analysis →

Incannex Healthcare Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the IXHL research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for IXHL?

IXHL carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Incannex Healthcare Limited is an Australian pharmaceutical company focused on developing medicinal cannabinoid products.

Is IXHL a good stock to buy?

Stock Expert AI does not rate IXHL buy, sell or hold. Incannex Healthcare Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IXHL stock price today?

The last price recorded for Incannex Healthcare Inc. (IXHL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for IXHL?

The main risks for Incannex Healthcare Limited include the uncertainty of clinical trial outcomes, potential delays in regulatory approvals, and competition from established pharmaceutical companies.

What are the key factors to evaluate for IXHL?

Incannex Healthcare Inc. (IXHL) holds a MoonshotScore in the low range. Analysts target $18.22 (+947%). Focus on cannabinoid-based therapies positions the company in a high-growth, albeit risky, segment of the pharmaceutical market. Not financial advice.

How frequently does IXHL data refresh on this page?

IXHL's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IXHL's recent stock price performance?

Incannex Healthcare Inc. (IXHL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabinoid-based therapies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IXHL overvalued or undervalued right now?

Incannex Healthcare Inc. (IXHL) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of IXHL?

Fractional-share availability for Incannex Healthcare Inc. (IXHL) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.